leisure time -WSS

leisure time

author：knowledge 2025-09-29 06:28:54 - browse：9922

Balance innovation — A federal judge made a key ruling in a lawsuit challenging a new drug pricing program Adobe

WASHINGTON — A federal court judge allowed a new Medicare drug price negotiation program to proceed while the court deliberates whether it is constitutional.

The case centers on Democrats’ new law, which empowered the Medicare program to start negotiating lower prices for certain medicines that are especially expensive for the government. Judge Michael Newman, a Trump appointee to the U.S. District Court for the Southern District of Ohio, ruled against the U.S. Chamber of Commerce, which had sued the federal government and asked for the program to be stopped while litigation continues.

Medicare officials announced the first 10 drugs they would negotiate over last month, and the deadline for the pharmaceutical companies to sign agreements to start bargaining is Oct. 1. The Chamber of Commerce had requested a decision on the preliminary injunction by that date.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Ebola vaccine can save some who are already sick, per new study

leisure time

WSS

AMAs digital advisors table RPM coding reform proposal, again

Report cites 'urgent' need to recruit more diverse clinical trial participants

Tome Biosciences co

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Cybersecurity threat forces Lurie Children's to take systems offline

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

hotspot

leisure time

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Vertigo drug brings hope for rare neuron disorder, Niemann

Affirmative action in medical school literally saved lives

FDA drug safety: Singulair case shows systemic surveillance flaws

Activists slam private health insurers over coverage restrictions

Artificial intelligence use in health care faces greater scrutiny in 2024

Jerome Adams on the need for new antivirals for Covid

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Resistance to opioid

Wikipedia

Medicare drug price negotiation’s day in court

Long Covid research funding gets a major boost from NIH

Cybersecurity threat forces Lurie Children's to take systems offline

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Latigo launches with $135 million for Vertex

Abbott's new heart device gets FDA advisory panel nod

leisure time

leisure time

hotspot

entertainment